Enlivex (ENLV): CEO Details Why the Company Is Pioneering a Dual Biotech and Digital Asset Strategy

Send us Fan MailIn this episode of WTR Small-Cap Spotlight, Oren Hershkovitz, CEO of Enlivex, joins host Tim Gerdeman, Vice Chair, Co-Founder, and CMO of Water Tower Research, along with Dr. John Roy, WTR’s Senior Equity Research Analyst. The conversation explores the evolved corporate strategy of Enlivex, a clinical-stage immunotherapy company that has pioneered a dual-pillar approach combining traditional drug development with a high-exposure digital asset treasury (DAT). Unlike companies that focus their treasuries on Bitcoin, Enlivex is the first public company to center its strategy around prediction markets, specifically the RAIN decentralized protocol. This novel approach allows the company to potentially leverage yield enhancement activities from its digital assets to aggressively fund the clinical development of its lead immunotherapy candidate, Allocetra, currently in late-stage trials for age-related osteoarthritis.